医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Rigaku Holdings Corporation: Approval of Listing on the Tokyo Stock Exchange Prime Market

2024年09月24日 PM10:00
このエントリーをはてなブックマークに追加


 

TOKYO

Rigaku Holdings Corporation, a global solution partner for X-ray analysis (headquarters: Akishima, Tokyo; president and CEO: Jun Kawakami; “Rigaku”), has been approved for a new listing of its shares of common stock on the Tokyo Stock Exchange Prime Market today. The listing date is scheduled for October 25, 2024, and from the same date, our common stock will trade on the exchange.

Note: This document is a press release intended for public announcement regarding the approval of Rigaku’s listing on the Tokyo Stock Exchange Prime Market. It has not been prepared for the purpose of soliciting investments or any similar acts, whether within or outside Japan.

This press release does not constitute an offer or sale of securities in the United States. The shares may not be offered or sold in the United States absent registration or an exemption from requirement. If any public offering of the shares is made in the United States, it will be by means of a prospectus that may be obtained from us or the selling shareholders and that will contain detailed information about us and our management, as well as our financial statements. No public offering of the shares of common stock of Rigaku will take place in the United States.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240920300374/en/

CONTACT

Press Contact:

Sawa Himeno

Head of Communications Dept., Rigaku Holdings Corporation

+81 90 6331 9843

prad@rigaku.co.jp

同じカテゴリーの記事 

  • Rigaku Holdings Corporation: Approval of Listing on the Tokyo Stock Exchange Prime Market
  • YourChoice Therapeutics Begins Second Human Study for Hormone-Free Male Birth Control Pill
  • Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment of Bullous Keratopathy of the Cornea
  • Aurion Biotech在日本推出用于治疗大疱性角膜病变的Vyznova® (neltependocel)
  • 「ニューリフィックス®」ベータグルカンがデュシェンヌ型筋ジストロフィー治療薬として希少小児疾患および希少疾病用医薬品の指定を米国FDAから取得